THUR, AUGUST 11th, 2022 09:00 CET

New case reports of ChloraSolv presented in Journal of Wound Care supplement

During the last six months, RLS Global and ConvaTec have worked in close collaboration to collect clinical experiences of ChloraSolv from three different wound centers in the UK. Six case studies have been compiled into a report and published as a supplement in Journal of Wound Care, issue no 7 2022. The aim is to demonstrate the implementation of ChloraSolv in practice.

The clinical experience shows that ChloraSolv has strong debridement efficacy, as well as good safety and ease of use. It means that the technology can be used by any health care professional involved in wound care, regardless of their skills and experience. Therefore, it can easily be incorporated into all wound management pathways.

In total 30 patients were treated with ChloraSolv. Most of the patients in the case studies were previously unable to tolerate debridement due to the pain and discomfort it caused them, which greatly impaired healing. This has had a significant negative effect on their quality of life. The gentle action of ChloraSolv made the debridement acceptable and tolerable to the patient.

“RLS Global continues to work in close collaboration with ConvaTec to collect clinical data and experience of ChloraSolv. This is the first published report sharing data of the implementation of ChloraSolv in practice. We are of course very satisfied with the outcome and the fact that Journal of Wound Care is publishing the supplement”, says Karin Fischer, CEO, RLS Global.

“The conclusion that ChloraSolv can be used by all health care professionals and is gentle and efficient for the patients has a significant impact on the treatment of hard to heal wounds, from a health economic perspective”.  

Click to find full supplement.

ChloraSolv is a debriding gel, based on a unique hypochlorite technology, which is used with very good effect on leg ulcers and diabetic foot ulcers. The gel allows the gentle removal of devitalised tissue and promotes natural wound healing.1 ChloraSolv does not damage healthy tissue and is well tolerated by the patient.

  1. Eliasson B, Fagerdahl AM, Jönsson A, Apelqvist J. An open single arm multicenter pilot investigation to evaluate the debriding effect of amino acid buffered hypochlorite (ChloraSolv®) on chronic wounds covered with devitalized tissue during six weeks treatment. Journal of Wound Care (Accepted for publication).


RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag. The company was earlier listed on Aktietorget.

Karin Fischer, CEO, RLS Global
Telephone: +46 702 48 46 51